Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Volcano Acquires Last Piece Of Jomed, Will Raise Capital To Cover Deal

This article was originally published in The Gray Sheet

Executive Summary

Volcano Therapeutics will add its Virtual Histology imaging software to the 1,200 installed U.S. Jomed intravascular ultrasound imaging systems following the acquisition of Jomed's IVUS and functional measurement instrument business

You may also be interested in...



Financings In Brief

NitroMed stent investment: Boston Scientific extends R&D collaboration with pharmaceutical firm through 2005 to develop nitric oxide elution compounds that can be used on vascular stents to "complement" Taxus line. The agreement, which expands the firms' original 2001 deal, consists of a $3 mil. up-front payment, adding to the $4 mil. equity investment and $1.5 mil. R&D payments already made by Boston Scientific. NitroMed also will receive milestone payments for development and commercialization targets, as well as royalties if a product is brought to market. Over the past year, Boston Scientific also has invested in Rubicon Medical, 3F Therapeutics and Innovia...

Financings In Brief

NitroMed stent investment: Boston Scientific extends R&D collaboration with pharmaceutical firm through 2005 to develop nitric oxide elution compounds that can be used on vascular stents to "complement" Taxus line. The agreement, which expands the firms' original 2001 deal, consists of a $3 mil. up-front payment, adding to the $4 mil. equity investment and $1.5 mil. R&D payments already made by Boston Scientific. NitroMed also will receive milestone payments for development and commercialization targets, as well as royalties if a product is brought to market. Over the past year, Boston Scientific also has invested in Rubicon Medical, 3F Therapeutics and Innovia...

IVUS Utility In Drug-Eluting Stent Trials Underscored By TAXUS IV, ASPECT

Intravascular ultrasound is able to measure drug-eluting stent efficacy with a smaller sample size than angiography or clinical endpoints, according to Neil Weissman, MD, Washington Hospital Center

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel